New therapies on the market and in clinical trials makes this a quickly changing time for clinicians who treat patients with Duchenne Muscular Dystrophy (DMD) and Limb-Girdle Muscular Dystrophy (LGMD). Neuromuscular experts who attended national and international conferences provide updates on these changes, the latest data, and the impact on the clinical management of patients with DMD and LGMD.